Avecia Biotechnology and TriLink BioTechnologies Inc. have announced an alliance to offer customers scale-up of manufacturing for the entire lifecycle of oligonucleotide-based drug discovery, development and commercialization.
By adopting common technology platforms, Avecia and TriLink are offering an integrated management and technology solution that is designed to enable customers to transition from R&D and pre-clinical studies to clinical trials and beyond.
The companies are partnering to provide customers with a unified manufacturing approach to ensure transition between the pre-clinical and clinical phases of drug development.
This alliance is designed to offer a solution for drug developers looking to minimize the challenges and risks associated with transitioning from a research-grade vendor to an oligonucleotide development service and manufacturing company.
TriLink and Avecia are harmonizing their processes, so customers can enjoy a smooth changeover when scaling up for clinical trials.
"Avecia and TriLink share similar high standards for customer service and quality, so Avecia has always been our top recommendation to customers preparing to scale up," said Dr. Richard Hogrefe, CEO and President of TriLink.
"This alliance integrates our methods to give customers the most direct path from initial research to the clinic."
"We successfully transferred our technology to Trilink - now, together, we’ll be able to serve more clients in pre-clinical development and provide faster and smoother transfer into clinical development," added Detlef Rethage, President of Avecia Biotechnology Inc.